Tegretol is usually taken orally for 12 months, rarely up to a year and a half, and some patients can be treated with long-term oral antiplatelet therapy with Tegretol. It can be extended to one and a half years for those with a high risk of ischemia, a certain score and a low risk of bleeding. Tegretol is currently taken mainly in patients with acute myocardial infarction and after stenting, mostly in combination with aspirin to increase the strength of the antiplatelet. The two drugs are combined simultaneously for 12 months, and after one year, the treatment can be adjusted to monotherapy, usually with aspirin, which is usually not required to be taken orally for one and a half years. Some patients may not be able to tolerate aspirin, such as aspirin-associated asthma and aspirin-associated angioedema, and may be switched to antiplatelet therapy with Tegretol, which may be used for up to one and a half years. Tegretol is an ADP receptor antagonist, a potent antiplatelet agent, and the adverse effects of the drug are mainly bleeding, commonly from the skin mucosa, and in rare patients, gastrointestinal or intracranial bleeding may occur. Tegretol should be taken under the supervision of a physician and be aware of the risk of bleeding.